

Hikma to present at 41st Annual J.P. Morgan Healthcare Conference

London, 9 January 2023 – Hikma Pharmaceuticals PLC (Hikma) will present this week at the 41st Annual J.P. Morgan Healthcare Conference. Bassam Kanaan, EVP, Corporate Development and M&A and Susan Ringdal, EVP, Strategic Planning and Global Affairs will present virtually and answer questions at 9:45 AM Pacific Standard Time (5:45 PM GMT) on Wednesday 11 January.

A live webcast of the presentation will be available by following this <u>link</u>, and will remain available for 30 days. A copy of the presentation will be available on the <u>Investors</u> section of Hikma's website.

- ENDS -

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com